- Home
- IBRX vs GSHD Comparison
IBRX vs GSHD Comparison
Compare IBRX & GSHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- GSHD
- Stock Information
- Founded
- IBRX 2014
- GSHD 2003
- Country
- IBRX United States
- GSHD United States
- Employees
- IBRX N/A
- GSHD N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- GSHD Specialty Insurers
- Sector
- IBRX Health Care
- GSHD Finance
- Exchange
- IBRX Nasdaq
- GSHD Nasdaq
- Market Cap
- IBRX 2.3B
- GSHD 2.2B
- IPO Year
- IBRX N/A
- GSHD 2018
- Fundamental
- Price
- IBRX $2.58
- GSHD $73.99
- Analyst Decision
- IBRX Strong Buy
- GSHD Hold
- Analyst Count
- IBRX 6
- GSHD 10
- Target Price
- IBRX $9.83
- GSHD $101.50
- AVG Volume (30 Days)
- IBRX 9.7M
- GSHD 399.2K
- Earning Date
- IBRX 11-10-2025
- GSHD 10-22-2025
- Dividend Yield
- IBRX N/A
- GSHD 7.99%
- EPS Growth
- IBRX N/A
- GSHD 68.12
- EPS
- IBRX N/A
- GSHD 1.14
- Revenue
- IBRX $56,600,000.00
- GSHD $353,231,000.00
- Revenue This Year
- IBRX $629.94
- GSHD $16.87
- Revenue Next Year
- IBRX $109.91
- GSHD $22.03
- P/E Ratio
- IBRX N/A
- GSHD $65.13
- Revenue Growth
- IBRX 4227.22
- GSHD 25.01
- 52 Week Low
- IBRX $1.83
- GSHD $64.41
- 52 Week High
- IBRX $6.82
- GSHD $130.39
- Technical
- Relative Strength Index (RSI)
- IBRX 54.54
- GSHD 53.35
- Support Level
- IBRX $2.30
- GSHD $64.41
- Resistance Level
- IBRX $2.67
- GSHD $76.94
- Average True Range (ATR)
- IBRX 0.12
- GSHD 2.93
- MACD
- IBRX 0.01
- GSHD 1.39
- Stochastic Oscillator
- IBRX 75.68
- GSHD 76.50
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.